Peter Libby: Mast Cells in Cardiovascular Disease
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Mass General Brigham Hospital, shared a post on LinkedIn:
“Every leukocyte class shall have its day in atherosclerosis. With an international team, we summarize the current evidence supporting mechanisms by which mast cells can participate in this disease. Inflammation has many faces, and reaginic antibody (IgEs) can link adaptive to innate immunity unleashing a multitude of mast cell mediators that can modulate arterial and microvascular biology.”
Title: Mast cells in cardiovascular disease: Fibrosis, angiogenesis and atherogenesis
Authors: Gabriel Bueno, Ilze Bot, Anish A. Kanhai, Roberta Stilhano, Peter Libby, Guido R.Y. De Meyer, Leonardo Martin
Stay informed with Hemostasis Today.
-
Jul 23, 2026, 20:10Mohammad Alzoubi: One Month of Dual Antithrombotic Therapy After PCI Was Non-Inferior to 12 Months
-
Jul 23, 2026, 20:08Ahmed Bennis: Calcitriol Replenishment May Mitigate Ischemic Risk in MASLD
-
Jul 23, 2026, 20:06Mitsuaki Sawano: Can Cardiovascular Risk Prediction Models Developed in One Population be Reliably Applied to Another?
-
Jul 23, 2026, 20:05Abdul Muqtadir Abbasi: Hemostasis Isn’t About Memorizing Factor Numbers – It’s About Recognizing Patterns
-
Jul 23, 2026, 19:40Maureen Macharia: How Apixaban Transformed Modern Anticoagulation
-
Jul 23, 2026, 19:30Jordan Agay: Why We Need to Track the Neurological Costs of Anemia
-
Jul 23, 2026, 19:25William Archibald: Key Takeaways on VTE Cost-Effectiveness and Cancer Associated Thrombosis from ISTH 2026
-
Jul 23, 2026, 19:17Diego López Santos: Donation after Donation, I Just Reached 100
-
Jul 23, 2026, 19:11Jecko Thachil: Chlorosis May Have Represented Iron Deficiency in the 19th Century